Pasireotide - Novartis

Drug Profile

Pasireotide - Novartis

Alternative Names: Pashireochidopamo salt; pasireotide LAR; Pasireotide pamoate; SIGNIFOR; SIGNIFOR LAR; SIGNIFOR LAR Kit; SOM 230; SOM 230 LAR; SOM230C

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Antineoplastics; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Pituitary ACTH hypersecretion
  • Phase II Cluster headache; Pituitary cancer
  • Discontinued Carcinoid tumour; Gastrointestinal cancer; Gastrointestinal disorders; Liver cancer; Malignant melanoma; Meningioma; Merkel cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Radiation injuries; Uveal melanoma

Most Recent Events

  • 08 Nov 2018 Discontinued - Phase-I for Gastrointestinal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IM) (Novartis pipeline, November 2018)
  • 08 Nov 2018 Discontinued - Phase-I for Malignant melanoma (Metastatic disease) in Germany, Switzerland (SC) (Novartis pipeline, November 2018)
  • 08 Nov 2018 Discontinued - Phase-I for Merkel cell carcinoma (Metastatic disease) in Switzerland, Germany (SC) (Novartis pipeline, November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top